Newamsterdam Pharma CO NV

NewAmsterdam Pharma and Menarini Group announced a positive opinion from the EMA's CHMP recommending marketing authorization for Ubeslo and Evlarco, key treatments for cardiovascular disease.

NewAmsterdam Pharma's Chief Operating Officer, Douglas Kling, is resigning to become CEO of another clinical-stage biotech company, effective August 14, 2026.

NewAmsterdam Pharma Company N.V. announced shareholder approval of the 2026 Employee Stock Purchase Plan and re-appointment of directors at its annual general meeting.

NewAmsterdam Pharma reported Q1 2026 financial results, highlighting progress in obicetrapib clinical trials and maintaining a strong cash position.

NewAmsterdam Pharma Company N.V. announced the departure of Chief Accounting Officer Louise Kooij effective August 31, 2026.

NewAmsterdam Pharma released an updated investor presentation highlighting positive clinical trial data for obicetrapib in cardiometabolic diseases and Alzheimer's, alongside strong financial positioning.

NewAmsterdam Pharma reports Q1 2026 results with ongoing clinical trials for obicetrapib, a potential LDL-C lowering therapy, and European regulatory reviews progressing.

NewAmsterdam Pharma reported a significant increase in net loss for Q3 2025, driven by decreased revenue and warrant fair value changes, despite reduced R&D expenses.

NewAmsterdam Pharma reported a significant reduction in net loss for Q2 2025, driven by increased license revenue and decreased R&D expenses, alongside positive Alzheimer's disease biomarker data for obicetrapib.

NewAmsterdam Pharma reports its financial results for the first quarter of 2025, highlighting revenue from its Menarini license and progress in clinical development.

NewAmsterdam Pharma announced positive topline results from its Phase 3 BROOKLYN trial and provided a financial update for the quarter ended September 30, 2024.

NewAmsterdam Pharma's Q2 2024 report details financial results, progress in clinical trials, and a strengthened cash position, while also noting ongoing risks and challenges.

NewAmsterdam Pharma's 10-K filing highlights successful Phase 3 trials for obicetrapib and its fixed-dose combination, paving the way for potential regulatory submissions and commercialization.

NewAmsterdam Pharma's recent SEC filing outlines the terms of its ordinary shares and warrants, including redemption options and anti-dilution adjustments.

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., sold 105,000 shares of common stock on July 20, 2026.

Louise Frederika Kooij, Chief Accounting Officer at NewAmsterdam Pharma Co. N.V., reported transactions involving the acquisition and disposition of ordinary shares.

Louise Kooij, Chief Accounting Officer at NewAmsterdam Pharma, executed a series of transactions involving the purchase and sale of ordinary shares, including those acquired through stock options, under a Rule 10b5-1 trading plan.

NewAmsterdam Pharma Director Louis G. Lange sold 44,619 ordinary shares in two transactions under a Rule 10b5-1 plan.

NewAmsterdam Pharma CEO Michael H. Davidson has scheduled the exercise of options and subsequent sale of 443,707 ordinary shares for March 2, 2026, under a Rule 10b5-1 plan.

NewAmsterdam Pharma CEO Michael H. Davidson exercised options and sold 306,293 ordinary shares, also transferring 285,715 shares to a Grantor Retained Annuity Trust.

NewAmsterdam Pharma Company N.V. has issued a proxy statement detailing the agenda for its 2026 Annual General Meeting of Shareholders, including proposals on financial accounts, director reappointments, and an employee stock purchase plan.

NewAmsterdam Pharma announces its 2025 Annual General Meeting (AGM) to be held on June 4, 2025, in Amsterdam, featuring proposals including director appointments, auditor ratification, and executive compensation.

NewAmsterdam Pharma will hold its annual general meeting of shareholders on June 5, 2024, in Amsterdam.

Bain Capital Life Sciences entities have sold a significant portion of their holdings in NewAmsterdam Pharma, dropping their beneficial ownership below the 5% reporting threshold.

Bain Capital Life Sciences entities sold 4.8 million NewAmsterdam Pharma shares for $168.4 million, reducing their collective beneficial ownership to approximately 6.4%.

Bain Capital entities filed an amended Schedule 13D for NewAmsterdam Pharma, maintaining a 9.99% beneficial ownership stake, while Nicholas Downing resigned from the board.

Frazier Life Sciences Public Fund increases its stake in NewAmsterdam Pharma Company N.V. following a merger with Frazier Life Sciences Public Overage Fund.

Forbion Capital Partners and related entities have filed an amendment to their beneficial ownership in NewAmsterdam Pharma Company N.V., reporting an aggregate stake of 8.3%.

Frazier Life Sciences funds have updated their beneficial ownership in NewAmsterdam Pharma, detailing recent share purchases and clarifying ownership attribution.

Capital World Investors has reported a 10.4% beneficial ownership stake in NewAmsterdam Pharma Company N.V. as of May 29, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 8,765,811 shares, representing 7.6% of NewAmsterdam Pharma Company NV's common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a 5.7% beneficial ownership stake in NewAmsterdam Pharma Company NV's common stock as of December 31, 2025.

Capital World Investors has increased its beneficial ownership in NewAmsterdam Pharma Company N.V. to 8.7% of common stock.

Capital World Investors reports a 7.5% passive stake in NewAmsterdam Pharma Company N.V., holding over 8.3 million shares.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.9% of NewAmsterdam Pharma Company N.V.'s Ordinary Shares as of March 31, 2025.